

Bangladesh Support for Rotavirus Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Bangladesh		
2. Vaccines Grant number: 18-BGD-13b-X Cash support grant number: 18-BGD-08b-Y		
3. Date of Decision Letter: 15 June 2017		
4. Date of the Partnership Framework Agreement: 24 June 2013		
5. Programme title: New Vaccine Support (NVS), Rotavirus Routine		
6. Vaccine type: Rotavirus		
7. Requested product presentation and formulation of vaccine: Rotavirus, 2 dose(s) schedule		
8. Programme duration¹: 2018		
9. Programme Budget (indicative): (subject to the terms of the partnership framework agreement)		
	2018	Total ²
Programme Budget (US\$)	US\$4,275,500	US\$4,275,500
10. Vaccine introduction grant (in US\$): 2,696,500 to be used within 12 months of disbursement. Payable up to six months before vaccine introduction.		
11. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement) ³		
Type of supplies to be purchased with Gavi funds in each year	2018	
Number of Rotavirus vaccines doses	1,900,500 ⁴	
Annual Amounts (US\$)	US\$4,275,500	
12. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.		
13. Self-procurement: Not applicable.		

¹ This is the entire duration of the Programme.

² This is the total amount endorsed by Gavi for the entire duration of the Programme.

³ This is the amount that Gavi has approved.

⁴ This represents the number of Rotavirus vaccine doses for the implementation period of Oct-Dec 2018. Gavi is only able to approve support for the period covered by the Comprehensive Multi Year Plan (cMYP).

14. Co-financing obligations: Reference code: 18-BGD-13b-X-C

According to the co-financing policy, the Country falls within the group Preparatory transition. The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2018
Number of vaccine doses	217,500
Number of AD syringes	
Number of re-constitution syringes	
Number of safety boxes	
Value of vaccine doses (US\$)	US\$474,519
Total co-financing payments (US\$) (including freight)	US\$487,500

15. Operational support for campaigns: Not applicable

16. Additional reporting requirements:

Country shall deliver the following documents by the specified due dates as part of the conditions to the approval and disbursements of the future annual amounts: Not applicable

Reports and other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	May
In accordance with applicable Gavi processes, Country shall report on programmatic performance.	As per agreed schedule for each indicator in the Grant Performance Framework
In accordance with applicable Gavi processes, Country shall report on financial performance through periodic financial reports on all cash support	- Periodic 6 monthly financial report with variance analysis due 45 days after period end - Detailed budget activity reporting - Asset listings
In accordance with applicable Gavi processes, Country shall report on financial performance through annual financial reports on all cash support	Annual financial report with variance analysis due 3 months following end of Country's fiscal year.
External Audit Report	6 months after end of grant (18 months after Gavi disbursement of VIG funds)

17. Financial clarifications: Not applicable

18. Other conditions: In line with the duration of the current cMYP, this Decision Letter only approves support through 2018. Upon endorsement of the new cMYP 2018-2022 Gavi will be able to approve the remaining Rotavirus vaccine doses.

Signed by,



On behalf of Gavi

Hind Khatib-Othman

Managing Director, Country Programmes

15 June 2017